"MOM ALWAYS SAID, 'DON'T FOLLOW THE CROWD,' but she never worked on Wall Street, and she never invested in biotech stocks.
The biotech sector is now officially in play following AstraZeneca's $15.6 billion cash takeover of MedImmune, and speculators are placing bets about the next takeover target.
Biogen Idec, Celgene and Dendreon are attracting bullish call-trading, but the short-term momentum seems to be building behind Biogen.
Biogen stock jumped 4% on the AstraZeneca merger news. Call-trading remains active and indicates speculators are expecting Biogen stock to jump past $50 ..."
